Clinical Trial

A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes

Study acronym: WAVE T1D
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This multi-center randomized controlled trial will assess the safety and efficacy of ATG followed by either adalimumab or verapamil in preserving insulin secretion 2 years from randomization in persons aged 9 to \<21 with recent-onset stage 3 T1D.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2025-07-02; most recent amendment 2026-05-29.
Status change: Not Yet Recruiting → Recruiting 2026-03-13
Status change: Withdrawn → Not Yet Recruiting 2026-02-24
Status change: Not Yet Recruiting → Withdrawn 2026-02-18
Trial Details
NCT Number NCT07061574
Lead Sponsor City of Hope Medical Center
Collaborators: Jaeb Center for Health Research
Conditions Type 1 Diabetes, New Onset
Enrollment 120 participants
Start Date 2026-03-10
Primary Completion 2030-04-15 (estimated)
Study Completion 2031-04-15 (estimated)
Updated on ClinicalTrials.gov 2026-08-04